Paxlovid自问世以来,在全球范围内被广泛关注和讨论,并在COVID-19的治疗中发挥了重要作用。临床试验结果表明,Paxlovid在降低重症高风险人群的住院和死亡风险方面显示出显著的疗效,且Paxlovid获得了美国FDA和欧盟EMA的批准,以及WHO指南的唯一强烈推荐,这...
[2] Parums DV. Editorial: Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients. Med Sci Monit. 2022;28. [3] Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized...
[2] Parums DV. Editorial: Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients. Med Sci Monit. 2022;28. [3] Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, ...
[2] Parums DV. Editorial: Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients. Med Sci Monit. 2022;28. [3] Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized...
1.Hiremath S,McGuinty M,Argyropoulos C,Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD.CJASN.2022,17: 1247–1250. 2.Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants.Am J Transplant. 2022,00:1-2. ...
The government soon will stop paying for the COVID drug that has proved to be the most effective at keeping patients alive and out of the hospital.
COVID-19 的治疗。研究结果表明，尼马瑞韦和利托那韦可以帮助最近冠状病毒检测呈阳性的人避免去医院。本...
4. Cully M. A tale of two antiviral targets - and the COVID-19 drugs that bind them. Nat Rev Drug Discov. 2022;21(1):3-5. 5. 国家药监局应急附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装进口注册。国家药品监督管理局,XZXK-2022-120。
PAXLOVID_oral_solid.pdf#:~:text=The%20monograph%20of%20nirmatrelvir%2Fritonavir%20states%20that%20the%20drug,into%20the%20nirmatrelvir%2Fritonavir%20resources%20on%20the%20BCCDC%20website.5. Hiremath S, McGuinty M, Argyropoulos C, et al. Prescribing Nirmatrelvir/Ritonavir for COVID-...
1.Hiremath S,McGuinty M,Argyropoulos C,Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD.CJASN.2022,17: 1247–1250. 2.Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants.Am J Transplant. 2022,00:1-2. ...